{'fraction_non_alphanumeric': 0.016877637130801686, 'fraction_numerical': 0.006329113924050633, 'mean_word_length': 5.089743589743589, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New systemic drugs in the treatment of gastrointestinal cancer.

Paclitaxel has shown a significant activity on esophageal cancer in a phase II trial. Irinotecan has established the single-agent efficacy on both gastric and colorectal cancer. Docetaxel has attained a significant activity on advanced gastric cancer and a 29% response rate on pancreatic cancer in a phase II trial. Tomudex has shown comparable activity to leucovorin and 5-fluorouracil in colorectal cancer.